Gigantism Market

Market Overview:

The 7 major gigantism markets reached a value of USD 1,128.0 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,955.6 Million by ​2035​, exhibiting a growth rate (CAGR) of 5.13% during 2025-2035.

The gigantism market has been comprehensively analyzed in IMARC's new report titled "Gigantism Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Gigantism is an uncommon endocrine disorder that results from overproduction of growth hormone (GH) from the pituitary gland in childhood and is characterized by abnormal height and disproportionate growth of bones. Most cases are linked with pituitary adenomas—benign tumors that trigger excess secretion of GH. Accelerated growth, enlarged facial appearance, hyperhidrosis, arthralgia, weakness of muscles, and metabolic disturbances like insulin resistance are some common presentations of gigantism. If not treated, it can result in serious complications, such as cardiovascular disease and shortened life expectancy. Clinical examination, biochemical laboratory tests, and imaging procedures are involved in the diagnosis of gigantism. Oral glucose tolerance tests (OGTT) and insulin-like growth factor-1 (IGF-1) testing are routinely employed to evaluate GH hypersecretion. MRI scans of the pituitary gland also identify adenomas responsible for overproduction of GH. Therapeutic measures aim at normalization of GH levels and treatment of complications. The initial therapy consists of transsphenoidal removal of pituitary tumors followed by medical treatment in the form of somatostatin analogs (octreotide, lanreotide), GH receptor blockers (pegvisomant), and dopamine agonists (cabergoline). If surgical intervention and drug treatments fail, radiotherapy is employed to manage GH secretion.

The rising incidence of pituitary adenomas, the direct cause of gigantism, is a significant market growth driver, which in turn is increasing demand for efficient treatments. Technical advancements in diagnostic equipment, such as high-resolution MRI and GH and IGF-1 biomarker-based assays, are enhancing early detection rates, resulting in timely interventions. In addition, increasing use of targeted pharmacological treatment, including long-acting somatostatin analogs (octreotide LAR, lanreotide) and GH receptor antagonists (pegvisomant), is greatly improving disease control, especially in those not candidates for surgical resection. The industry is also helped by continued research into next-generation GH inhibitors and combination treatments with the goal of enhancing treatment effect while reducing side effects. Biopharmaceutical firms are currently formulating new products, such as sustained-release injectables and oral somatostatin analogs, to improve patient compliance and convenience. Additionally, expanding R&D spending on monoclonal antibodies against GH pathways is a paradigm-changing strategy in treatment approaches. The increasing emphasis on personalized medicine and companion diagnostics to individualize therapy according to genetic information is likely to further drive the gigantism market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the gigantism market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for gigantism and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gigantism market in any manner.

Key Highlights:

• Gigantism is extremely rare, affecting about 3 per million individuals, with most cases linked to excessive growth hormone (GH) secretion.
• Around 95% of cases result from GH-secreting pituitary adenomas, while rare instances involve ectopic GH or GHRH production from tumors.
• AIP gene mutations appear in 29% of cases, while Xq26 chromosome duplications contribute to early-onset gigantism, typically before age 5.
• Gigantism increases mortality rates by 2–3 times, mainly due to cardiovascular and respiratory complications resulting from prolonged GH excess.
• Surgery cures 80% of cases, with medical therapies and radiotherapy used when tumors persist, or surgery is unfeasible.

Drugs:

Lanreotide, produced by Ipsen, is a somatostatin analogue employed to manage gigantism through the inhibition of overproduction of growth hormone. It is administered through deep subcutaneous injection and controls abnormal growth and related symptoms. Its long-acting nature provides prolonged efficacy, minimizing treatment burden in patients who need suppression of growth hormone.

Pasireotide from Recordati is a somatostatin analogue acting against excess growth hormone secretion in gigantism. It acts on several somatostatin receptor subtypes, suppressing GH release and lowering IGF-1 levels. Pasireotide provides a new option for resistant patients, managing symptoms and controlling disease activity in pediatric and adult gigantism.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the gigantism market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the gigantism market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current gigantism marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the gigantism market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the gigantism market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the gigantism market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of gigantism across the seven major markets?
• What is the number of prevalent cases (​​2019-2035​​) of gigantism by age across the seven major markets?
• What is the number of prevalent cases (​​2019-2035​​) of gigantism by gender across the seven major markets?
• How many patients are diagnosed (​​2019-2035​​) with gigantism across the seven major markets?
• What is the size of the gigantism patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of gigantism?
• What will be the growth rate of patients across the seven major markets?

Gigantism: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for gigantism drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gigantism market?
• What are the key regulatory events related to the gigantism market?
• What is the structure of clinical trial landscape by status related to the gigantism market?
• What is the structure of clinical trial landscape by phase related to the gigantism market?
• What is the structure of clinical trial landscape by route of administration related to the gigantism market?